Biosimilar for HER2+ breast cancer: Overall response rate matches reference trastuzumab
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast ...
Nov 22, 2019
0
2